Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD) and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this study, we investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Using the Bielschowsky silver-staining method, we were able to differentiate between four types of plaques described earlier: diffuse, primitive, classic and compact. While diffuse plaques represent the early stage of plaque formation, primitive and classic plaques are thought to represent later stages of plaque development. We investigated serial sections of paraffin-embedded cortices of ten clinically diagnosed and histopathologically confirmed AD patients and ten patients with no clinical history of dementia. We found plaques in the brains of both nondemented and demented persons using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the group of clinically nondemented persons, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger portion of lesions in the group of AD brains. IL-6 could not be detected in plaques of patients without dementia. Many IL-6-positive plaques were found in six of the AD brains and to a smaller extent in the other four AD cases. In the six cases with a large number of IL-6-positive plaques, IL-6 was found in a significantly higher…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interleukin-6, a typical SASP mediator, is upregulated in the aged brain and in AD [96,97,98] and its overexpression has been shown to drive neurodegeneration in vivo [99].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
In the citing paper
“Most notably, IL-6, IL-1β, TGF-β and TNF-α levels have been reported to be elevated in AD brain tissue [96,97,212,213,214]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Baumann, H., & Gauldie, J. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90137-6 · Cited by 2,899
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B., & Mucke, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10061 · Cited by 1,006
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900
Roberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., & Graham, D. I. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.419 · Cited by 569
Excitatory amino acids and Alzheimer's disease
Greenamyre, J. T., & Young, A. B. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90143-7 · Cited by 484
Research works printed but not linked: 4
- Ikeda S, Glenner GG (1989) Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. Lab Invest 60:113?122
- Jellinger K, Bancher C, Fischer P, Lassmann H (1992) Quantitative histopathologic validation of senile dementia of the Alzheimer type. Eur J Gerontol 3:146?156
- Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. Arch Pathol Lab Med 117:132?144
- Wisniewski HM, Terry RD (1973) Reexamination of the pathogenesis of the senile plaque. Prog Neuropathol 2:1?26
Cited by
Items 101–200 of 214
Tsuchiya, T., Park, K. C., Toyonaga, S., Yamada, S. M., Nakabayashi, H., Nakai, E., Ikawa, N., Furuya, M., Tominaga, A., & Shimizu, K. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.025 · Cited by 48
“Activated microglia, particularly those in the vicinity of neuritic plaques, have shown to be immunoreactive for IL-1, IL-6, and TNF-a (Griffin et al., 1989; Dickson et al., 1993; Huell et al., 1995).”
Poynter, M. E., & Daynes, R. A. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1525 · Cited by 44
Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576
Tehranian, R., Hasanvan, H., Iverfeldt, K., Post, C., & Schultzberg, M. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01592-0 · Cited by 48
p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia
Lin, H., Dixon, S. G., Hu, W., Hamlett, E. D., Jin, J., Ergul, A., & Wang, G. Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02909-0 · Cited by 45
“Increased IL-6 expression levels have been observed in brain specimens from AD patients [10] and are linked to diffuse plaques representing the early stage of plaque formation [11].”
BackgroundResultInfluentialGao, X., Chen, Y., & Cheng, P. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1338875 · Cited by 41
TDO as a therapeutic target in brain diseases
Yu, C., Pan, Z., & Luo, D. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9824-z · Cited by 42
The importance of inflammatory mechanisms for the development of Alzheimer’s disease
Eikelenboom, P., & Veerhuis, R. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00022-4 · Cited by 46
Meyer, R. P., Knoth, R., Schiltz, E., & Volk, B. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7553 · Cited by 39
Self-citationLicastro, F., & Chiappelli, M. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00034-4 · Cited by 42
Cheng, S., Zhang, C., Xu, C., Wang, L., Zou, X., & Chen, G. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.10.029 · Cited by 40
Bour, A. M. J. J., Westendorp, R. G. J., Laterveer, J. C., Bollen, E. L. E. M., & Remarque, E. J. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00128-5 · Cited by 42
Schumann, G., Hüell, M., Machein, U., Hocke, G. M., & Fiebich, B. L. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.02009.x · Cited by 44
Avenanthramide-C Restores Impaired Plasticity and Cognition in Alzheimer’s Disease Model Mice
Ramasamy, V. S., Samidurai, M., Park, H. J., Wang, M., Park, R. Y., Yu, S. Y., Kang, H. K., Hong, S., Choi, W., Lee, Y., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01707-5 · Cited by 38
Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study
Elwan, O., Madkour, O., Elwan, F. Z., Mostafa, M., Helmy, A. A., Naseer, M. M. A., Abdelshafy, S., & Faiuomy, N. E. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00032-7 · Cited by 37
Kim, J., Lim, J., Yoo, I. D., Park, S., & Moon, J. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102735 · Cited by 40
“IL-6 contributes to early-stage amyloid plaque formation in human AD [53,54].”
BackgroundCellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
Potter, H. (1998) · Frontiers in Bioscience · doi:10.2741/a290 · Cited by 35
He, Y., Janssen, W. G. M., & Morrison, J. H. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981115)54:4<444::aid-jnr2>3.0.co;2-3 · Cited by 73
Kawashima, A., Harada, T., Imada, K., Yano, T., & Mizuguchi, K. (2008) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.07.002 · Cited by 39
Nam, H., Lee, Y., Kim, B., Lee, J.-W., Hwang, S., An, H., Chung, K. M., Park, Y., Hong, J., Kim, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29653-2 · Cited by 36
The emerging neuroprotective roles of exerkines in Alzheimer’s disease
Rody, T., Amorim, J. A. D., & Felice, F. G. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.965190 · Cited by 40
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2001.103002126.x · Cited by 37
Fiebich, B. L., Lieb, K., Berger, T., & Bauer, J. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00145-x · Cited by 36
Self-citationRole of the Brain in Interleukin-6 Modulation
Terreni, L., & De Simoni, M. G. (1998) · Neuroimmunomodulation · doi:10.1159/000026339 · Cited by 32
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
Wennström, M., Hall, S., Nägga, K., Londos, E., Minthon, L., & Hansson, O. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0145-y · Cited by 34
“close vicinity to Aβ1–42 plaques in these patients [19, 20].”
Can consuming flavonoids restore old microglia to their youthful state?
Jang, S., & Johnson, R. W. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00336.x · Cited by 40
Yasuhara, O., Matsuo, A., Terai, K., Walker, D. G., Berger, A. E., Akiguchi, I., Kimura, J., & McGeer, P. L. (1997) · Acta Neuropathologica · doi:10.1007/s004010050633 · Cited by 33
Pentraxins and Alzheimer's disease: At the interface between biomarkers and pharmacological targets
Osera, C., Pascale, A., Amadio, M., Venturini, L., Govoni, S. M., & Ricevuti, G. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.12.004 · Cited by 32
Lemke, R., H�rtig, W., Ro�ner, S., Bigl, V., & Schliebs, R. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19980115)51:2<196::aid-jnr8>3.0.co;2-8 · Cited by 30
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease
Zhou, X., Venigalla, M., Raju, R., & Münch, G. W. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02480-x · Cited by 36
“have shown that cortical senile plaques in AD patients display strong IL-6 immunoreactivity while no such immunoreactivity was found in the control brains (Bauer et al. 1991; Huell et al. 1995).”
BackgroundTilgner, J., Volk, B., & Kaltschmidt, C. (2001) · Glia · doi:10.1002/glia.1088 · Cited by 31
Self-citationAn Interleukin-6 Promoter Variant Is Not Associated with an Increased Risk for Alzheimer’s Disease
Depboylu, C., Lohmüller, F., Gocke, P., Du, Y., Zimmer, R., Gasser, T., Klockgether, T., & Dodel, R. C. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000076352 · Cited by 29
Fiebich, B. L., Hofer, T. J., Lieb, K., Hüell, M., Butcher, R. D., Schumann, G., Schulze‐Osthoff, K., & Bauer, J. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00055-6 · Cited by 31
Self-citationMartínez‐Cué, C., & Rueda, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186906 · Cited by 26
Effects of Immunomodulatory Substances on Phagocytosis of A by Human Microglia
Hjorth, E., Frenkel, D., Weiner, H., & Schultzberg, M. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/798424 · Cited by 27
“In the AD brain, activated microglia and astrocytes are present in the areas of neurodegeneration and amyloid plaques [10] and there is an increased production of proinflammatory cytokines such as interleukin- (IL)-1 [11] and IL-6 [12].”
Anti-inflammatory substances – a new therapeutic option in Alzheimer's disease
Hüll, M. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01339-2 · Cited by 30
Sackmann, V., Ansell, A., Sackmann, C., Lund, H., Harris, R., Hallbeck, M., & Nilsberth, C. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.022 · Cited by 23
Impact of IL-21-associated peripheral and brain crosstalk on the Alzheimer’s disease neuropathology
Agrawal, S., Baulch, J. E., Madan, S., Salah, S., Cheeks, S. N., Krattli, R. P., Subramanian, V. S., Acharya, M. M., & Agrawal, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04347-6 · Cited by 27
“Furthermore, IL-6 is reported to be a component of early-stage Aβ plaque formation [21] and is associated with synapse loss and learning deficits in AD mice [8].”
BackgroundQuillen, D., Hughes, T. M., Craft, S., Howard, T. D., Register, T. C., Suerken, C. K., Hawkins, G. A., & Milligan, C. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200095 · Cited by 26
“In animal models, blocking IL6 activity or inhibiting downstream Stat3 activation improves cognitive deficits and peripheral glucose intolerance.(12) Furthermore, inhibition of IL6 signaling in animal models has also been shown to decrease amyloid plaque burden in both the cortex and the hippocampus.”
BackgroundCouturier, J., Page, G., Morel, M., Gontier, C., Lecron, J., Pontcharraud, R., Fauconneau, B., & Paccalin, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100258 · Cited by 31
“Studies and clinical research in the last decades support the existence of a chronic inflammation process involved in amyloid plaque progression that contributes to AD-related lesions [3–5].”
Kaur, S., & Bansal, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105670 · Cited by 26
Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer’s disease
Fiebich, B. L., Hüll, M., Lieb, K., Schumann, G., Berger, T., & Bauer, J. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_26 · Cited by 26
Self-citationEnogieru, A. B., & Momodu, O. I. (2021) · The Botanical Review · doi:10.1007/s12229-021-09246-2 · Cited by 30
“Studies show that IL-6 staining in the hippocampus and cortex is strongly linked to Aβ plaques (Huell et al., 1995; Hampel et al., 2005).”
BackgroundBazan, N. G., Halabi, A., Ertel, M. K., & Petasis, N. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00034-1 · Cited by 26
Inflammatory Markers in Chronic Neurodegenerative Disorders with Emphasis on Alzheimer’s Disease
Walker, D. G. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-473-3_2 · Cited by 22
Neuron–microglia interactions in neuroinflammation
Mizuno, T. (2015) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12228 · Cited by 18
“IL-6 is present in the early stages of plaque formation.(48) Elevation of IL-6 is associated with altered cognitive function.”
BackgroundRösler, N., Wichart, I., & Jellinger, K. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01514-2 · Cited by 20
Neuroinflammation in kidney disease and dialysis
Chagas, Y. E. W., de Castro, P. A. S. V., & Silva, A. C. S. E. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115465 · Cited by 21
Targeting cytokine expression in glial cells by cellular delivery of an NF-κB decoy
Fisher, L., Samuelsson, M., Jiang, Y., Ramberg, V., Figueroa, R., Hallberg, E., Langel, Ü., & Iverfeldt, K. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn:31:03:209 · Cited by 19
“Upregulated levels of the inflammatory cytokines interleukin (IL)-1β and IL-6 have been detected both at early and later stages of AD, mainly expressed by activated microglia and reactive astrocytes in the vicinity of amyloid plaques ( Huell et al., 1995; Hull et al., 1996).”
BackgroundBrain interleukins and Alzheimer’s disease
Abdelhamed, H. G., Hassan, A. A., Sakraan, A., Al-Deeb, R. T., Mousa, D. M., Ezz, H. S. A., Noor, N. A., Khadrawy, Y. A., & Radwan, N. M. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01538-5 · Cited by 21
“IL-6 was found to participate in early-stage amyloid plaque formation in AD brains (Huell et al. 1995) by stimulating amyloid precursor protein (APP) synthesis (Ringheim et al. 1998) and tau phosphorylation (Quintanilla et al. 2004).”
Toro, V. C., Tehranian, R., Zetterström, M., Eriksson, G., Langel, Ü., Bartfai, T., & Lverfeldt, K. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:3:241 · Cited by 22
NOX2 in Alzheimer's and Parkinson's disease
Dustin, C. M., Shiva, S. S., Vazquez, A. L., Saeed, A., Pascoal, T. A., Cifuentes-Pagano, E., & Pagano, P. J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103433 · Cited by 20
Teoh, N. S. N., Gyanwali, B., Lai, M. K. P., Chai, Y. L., Chong, J. R., Chong, E. J. Y., Chen, C., Tan, C. S., & Hilal, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220971 · Cited by 19
“IL-6 is secreted by glial cells and has been found to be upregulated adjacent to amyloid-(cid:2) to form plaques indirectly via neuroinflammation [32] hence, many studies have been undertaken to better understand its role in the neurodegenerative process [10].”
Zhang, T., Luu, M. D. A., Dolga, A. M., Eisel, U. L. M., & Schmidt, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207280 · Cited by 21
“Studies revealed that SASP factors, including interleukin-1β (IL1β), interleukin-6 (IL-6), transforming growth factor-β (TGF-β), and tumor necrosis factor-α (TNF-α), were upregulated in AD, as evidenced by their elevation in the brains, CSF, and serum of AD patients (Blum-Degena et al., 1995; Dursun et al., 2015; Huel…”
BackgroundWong, M., Alshekhlee, A., Gold, P. W., & Licinio, J. (1996) · Neuroscience intelligence unit · doi:10.1007/978-1-4615-9695-0_2 · Cited by 16
Zhang, Y., Tatewaki, Y., Nakase, T., Liu, Y., Tomita, N., Thyreau, B., Zheng, H., Muranaka, M., Takano, Y., Nagasaka, T., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1227325 · Cited by 15
“, Interleukin-6 (IL-6) and C-reactive protein (CRP)] have been detected in brain plaques and neurofibrillary tangles in patients with AD (Iwamoto et al., 1994; Huell et al., 1995), suggesting the involvement of inflammatory processes in the etiology of AD.”
BackgroundDo Nonsteroidal Anti-Inflammatory Drugs Have a Protective Effect Against Dementia?
Muiswinkel, F. L. V., & Eikelenboom, P. (1996) · Drugs & Aging · doi:10.2165/00002512-199609010-00001 · Cited by 17
GRIMALDI, M., Navarra, P., Pozzoli, G., Preziosi, P., & Schettini, G. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9378 · Cited by 15
Coffee and its Active Compounds are Neuroprotective
Kim, J., & Lee, K. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409517-5.00046-2 · Cited by 23
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
“120,121 There has also been described an association between systemic in-fl ammation and AD, with plasma and CSF levels of IL-8 and MIP-1 β predicting elevated p-tau and total tau.”
Cai, F., Xue, S., Zhou, Z., Zhang, X., Kang, Y., Zhang, J., & Zhang, M. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.174202 · Cited by 15
Epistasis analysis links immune cascades and cerebral amyloidosis
Initiative, A. D. N., Benedet, A. L., Labbe, A., Lemay, P., Zimmer, E. R., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Mohades, S., Shin, M., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0436-z · Cited by 14
“Deregulation of immune response signaling in AD is evidenced by altered protein expression in the brain [63, 64].”
BackgroundDeveci, E., Kocacenk, T., Şahan, E., Yılmaz, O., Öztürk, A., & Kırpınar, İ. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1589176 · Cited by 13
Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap
Lieb, K., Fiebich, B. L., Hüll, M., Berger, T., & Bauer, J. (1997) · Cell and Tissue Research · doi:10.1007/s004410050810 · Cited by 13
Self-citationCombinatorial Treatment Effects in a Cell Culture Model of Alzheimer’s Disease
Beesley, S., Olcese, J., Saunders, C. E., & Bienkiewicz, E. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160459 · Cited by 10
Chiappelli, M., Tumini, E., Porcellini, E., & Licastro, F. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1327 · Cited by 11
Hasantari, I., Nicolas, N., Alzieu, P., Leval, L., Shalabi, A., Grolleau, S., & Dinet, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042272 · Cited by 12
“IL6 is a component of early-stage amyloid plaque formation in AD [45] and has been implicated in synapse loss of hippocampal neurons [46] and learning deficits in mice [47].”
BackgroundCytokines in dementia of the Alzheimer's type (DAT): relevance to research and treatment
Malek-Ahmadi, P. (1998) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(97)00027-4 · Cited by 10
Zhao, A. J., Balcer, L. J., Himali, J. J., O’Donnell, A., Rahimpour, Y., DeCarli, C. S., Gonzales, M. M., Aparicio, H. J., Ramos‐Cejudo, J., Kenney, R., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231425 · Cited by 12
“Loneliness-related inflammation has been associated with increased pro-inflammatory cytokines [32], which have in turn been seen to facilitate greater tau phosphorylation [33–36] and greater A (cid:2) deposition [31].”
BackgroundUyanık, K. Ç. P., Yiğin, A. K., Doğangün, B., & Seven, M. (2021) · Immunological Investigations · doi:10.1080/08820139.2020.1870489 · Cited by 10
“While IL6 and its receptors are normally expressed at low levels in brain (Gadient and Otten 1994a, 1994b), their levels are increased in various diseases and traumatic brain injury (Huell et al. 1995; Hang et al. 2004).”
BackgroundCharacterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation
Asgarov, R., Sen, M. K., Mikhael, M., Karl, T., Gyengési, E., Mahns, D. A., Malladi, C. S., & Münch, G. W. (2021) · The Cerebellum · doi:10.1007/s12311-021-01303-1 · Cited by 9
Hüll, M., Eistetter, J., Fiebich, B. L., & Bauer, J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)01003-9 · Cited by 10
Self-citationNadlinger, K., Birkmayer, J., Gebauer, F., & Kunze, R. (2002) · Neuroimmunomodulation · doi:10.1159/000049027 · Cited by 9
Koivisto, A. M. (2006) · Cited by 15
Weight loss in cancer and Alzheimer's disease is mediated by a similar pathway
Knittweis, J. (1999) · Medical Hypotheses · doi:10.1054/mehy.1998.0738 · Cited by 7
Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions
Licastro, F. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.5.639 · Cited by 7
Vascular-Related and Mediated Alterations in Alzheimer’s Disease
Sparks, D. L. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_20 · Cited by 6
Hampel, H. J., Scheloske, M., & Haslinger, A. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_6 · Cited by 6
Function of Astrocyte Cytochrome P450 in Control of Xenobiotic Metabolism
Volk, B., Meyer, R. P., & Knoth, R. (2004) · CRC Press eBooks · doi:10.1201/9781420039740.ch4 · Cited by 5
Self-citationDexamethasone does not ameliorate gliosis in a mouse model of neurodegenerative disease
Ye, X., Zou, G., Hou, J., Bi, H., Zhou, C., Wang, R., Xu, Y., Wang, C., Chen, G., Yin, Z., et al. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100817 · Cited by 4
“Two types of glial cells including astrocytes and microglia are involved in neuroinflammation, accompanied with changes in cytokines and chemokines such as interleukin 1β (IL1β) [8], IL6 [9], tumor necrosis factor α (TNFα) [10] and transforming growth factor β (TGFβ) [11].”
BackgroundSoureshjani, F. H., Kheirollahi, M., Yaghmaei, P., & Fattahjadnematalahi, S. (2021) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_143_19 · Cited by 4
“In addition, it has been demonstrated that IL‐6 is present in the early stages of plaque formation.[21] Our results indicate the downregulation of IL‐6 after treatment and decreased senile plaques when compared with AD rats.”
BackgroundResultCytokines as Therapeutic Agents in Neurological Disorders
Martin, D. P., Relton, J. K., Miller, G., Bendele, A. M., Fischer, N., & Russell, D. A. (1996) · Neuroscience intelligence unit · doi:10.1007/978-1-4615-9695-0_9 · Cited by 4
Charisis, S., Mourtzi, N., Scott, M. R., Ntanasi, E., Mamalaki, E., Hatzimanolis, A., Ramírez, A., Lambert, J., Yannakoulia, M., Kosmidis, M. H., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100018 · Cited by 3
Rösler, N., Wichart, I., & Jellinger, K. A. (2002) · Journal of Laboratory Medicine · doi:10.1046/j.1439-0477.2002.02031.x · Cited by 11
Kim, S., Jeong, H., Lee, K., Ryu, H.-H., Lee, K.-S., Moon, B., Cho, K. H., & Kim, H. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.09.021 · Cited by 3
Strategies to delay the onset of Alzheimer’s disease
Hüll, M. H., Fiebich, B. L., & Lieb, K. (2000) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-8393-1_13 · Cited by 3
Therapeutic strategies based on immunological hypotheses of Alzheimer’s disease
Möller, H. ‐. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_17 · Cited by 3
Neopterin Levels and Immune Activation in the Blood of Children with Down’s Syndrome
Licastro, F., Chiappelli, M., Porcellini, E., Rustica, M., & Corsi, M. M. (2005) · Pteridines · doi:10.1515/pteridines.2005.16.1.35 · Cited by 2
Cellular and molecular mechanisms of Alzheimer’s disease inflammation
Peery, H. E., Strohmeyer, R., & Rogers, J. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_1 · Cited by 2
Kim, S. J., Jeong, H., Kim, B. K., Kim, N. H., Kim, J. S., Choi, K., Lee, H. J., Kang, S., Shin, S. S., Kim, W. I., et al. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.12.002 · Cited by 2
Kaur, S., & Bansal, Y. (2021) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2021.100165 · Cited by 1
Rubiadin Alleviates Alzheimer’s Disease Pathology via NF-κB Pathway Regulation
Zhang, Y., Fan, J., Pan, J., Pan, J., Guo, W., & Zhang, Y. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin33497 · Cited by 1
“IL-6 is implicated in early amyloid plaque formation and specifically accumulates within cerebral plaques of AD patients [26].”
Postoperative Pain Management in Alzheimer’s Disease—a Review
Shahbaz, H., Shakir, N., Siddiqui, S. A., Shujauddin, S., Tariq, R., Khan, A. A., Zaffar, S., & Faizan, M. (2023) · Current anesthesiology reports · doi:10.1007/s40140-023-00582-0 · Cited by 1
Ng, T. K. S., Beck, T. L., Desai, P., Dhana, K., Wilson, R. S., Evans, D. A., & Rajan, K. B. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70002 · Cited by 4
The Involvement of Aβ in the Neuroinflammatory Response
Eikelenboom, P., van Gool, W. A., Rozemüller, A. J. M., Scheper, W., Veerhuis, R., & Hoozemans, J. J. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_4 · Cited by 2
Patterson, P. H. (2000) · Research and perspectives in neurosciences · doi:10.1007/978-3-642-59643-8_12 · Cited by 1
Neuroinflammation in Alzheimer’s Disease: Potential Targets for Disease-Modifying Drugs
Hüll, M., & Hampel, H. J. (2002) · Springer eBooks · doi:10.1007/978-3-662-05073-6_9 · Cited by 1
The Role of Cytokines in Alzheimer’s Disease
Hüll, M., Fiebich, B. L., Lieb, K., Volk, B., Berger, T., & Bauer, J. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5405-9_5
Self-citationAnálisis Multiplex de citoquinas intratecales en pacientes con deterioro cognitivo leve
Borja, E. R., Monge-Argilés, J. A., Soriano-Terol, M. A., & Muñoz‐Ruiz, C. (2011) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2011.05.002
Metadata
- Authors
- Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J.
- Affiliations
- University of Freiburg (DE)
- ORCID
- Strauss, Sylvia
- Venue
- Acta Neuropathologica
- Published
- 1995
- Volume
- 89
- Issue
- 6
- Pages
- 544-551
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2001259634
- Cited by
- 214
- References
- 53
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 5 · 2014: 8 · 2013: 2 · 2012: 4
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Forschung und Technologie
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- interleukin-6, Alzheimer's disease, amyloid plaques, plaque type, diffuse plaques, amyloid precursor protein, cerebral cortex, dementia, neuroinflammation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Chemistry, Humans, Immunohistochemistry, Middle Aged, Interleukin-6, Silver Staining
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.